Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

NCT06646354 is registered in ClinicalTrials.gov with Hyundai Pharm as lead sponsor.

NCT NCT06646354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06646354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
Lead sponsor
Hyundai Pharm
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 22, 2025
Completion date
December 31, 2028
Enrollment
125 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, primary hypercholesterolaemia